Actavis settles sublingual tablet patent spat with Orexo; FDA releases guidance on injectable packaging;

> Actavis Laboratories ($ACT) reached a settlement agreement on patent infringement litigation filed by Orexo. The suit was filed after Actavis filed for a generic version of Orexo's Abstral sublingual tablet for cancer pain. Under the agreement, Actavis can enter the market in June 2018. More

> The FDA released a draft guidance about injectable meds entitled "Selection of the Appropriate Package Type Terms and Recommendations for Labeling Injectable Medical Products Packaged in Multiple-Dose, Single-Dose, and Single-Patient-Use Containers for Human Use." More

> Ocular Therapeutix ($OCUL) said its intracanalicular depot for allergic conjunctivitis met its primary endpoint in a clinical trial. More